Baseline demographics and clinical characteristics
| Characteristic . | Value . |
|---|---|
| Number of subjects | 59 |
| Age, median (range), y | 42.5 (26-77) |
| Sex, n (%) | |
| Male | 33 (56) |
| Female | 26 (44) |
| Female donor to male recipient, n (%) | 14 (24) |
| HLA matching of donor/recipient, n (%) | |
| Matched | 53 (90) |
| Partially matched | 6 (10) |
| Conditioning intensity, n (%) | |
| Myeloablative | 44 (75) |
| Nonmyeloablative | 13 (22) |
| Unknown | 2 (3) |
| Stem cell source, n (%) | |
| Peripheral blood | 54 (92) |
| Bone marrow | 4 (7) |
| Unknown | 1 (1) |
| GVHD prophylaxis, n (%) | |
| CNI/MTX ± Other | 33 (56) |
| CNI/MMF | 11 (19) |
| CNI/sirolimus | 9 (15) |
| PTCy-based | 3 (5) |
| Other | 3 (5) |
| Median time from cGVHD to enrollment (range), m | 22 (1-161) |
| Clinical trial enrollment, n (%) | |
| KD025-208 | 17 (29) |
| KD025-213 | 42 (71) |
| Belumosudil dose, n (%) | |
| 200 mg daily | 27 (46) |
| 200 mg twice daily | 23 (39) |
| 400 mg daily | 9 (15) |
| NIH cGVHD global severity, n (%) | |
| Moderate | 11 (19) |
| Severe | 48 (81) |
| Number of organs involved, n (%) | |
| <4 | 20 (34) |
| ≥4 | 39 (66) |
| Median lines of prior therapy (range), n | 3 (1-6) |
| cGVHD response to last systemic therapy before enrollment, n (%) | |
| PR | 12 (20) |
| SD | 25 (42) |
| PD | 12 (20) |
| Unknown | 10 (17) |
| Median number of cycles of belumosudil therapy (range), n | 14 (1-57) |
| NIH lung score at baseline, n (%) | |
| 1 (FEV1 60%-79%) | 30 (51) |
| 2 (FEV1 40%-59%) | 23 (39) |
| 3 (FEV1 <40%) | 6 (10) |
| Characteristic . | Value . |
|---|---|
| Number of subjects | 59 |
| Age, median (range), y | 42.5 (26-77) |
| Sex, n (%) | |
| Male | 33 (56) |
| Female | 26 (44) |
| Female donor to male recipient, n (%) | 14 (24) |
| HLA matching of donor/recipient, n (%) | |
| Matched | 53 (90) |
| Partially matched | 6 (10) |
| Conditioning intensity, n (%) | |
| Myeloablative | 44 (75) |
| Nonmyeloablative | 13 (22) |
| Unknown | 2 (3) |
| Stem cell source, n (%) | |
| Peripheral blood | 54 (92) |
| Bone marrow | 4 (7) |
| Unknown | 1 (1) |
| GVHD prophylaxis, n (%) | |
| CNI/MTX ± Other | 33 (56) |
| CNI/MMF | 11 (19) |
| CNI/sirolimus | 9 (15) |
| PTCy-based | 3 (5) |
| Other | 3 (5) |
| Median time from cGVHD to enrollment (range), m | 22 (1-161) |
| Clinical trial enrollment, n (%) | |
| KD025-208 | 17 (29) |
| KD025-213 | 42 (71) |
| Belumosudil dose, n (%) | |
| 200 mg daily | 27 (46) |
| 200 mg twice daily | 23 (39) |
| 400 mg daily | 9 (15) |
| NIH cGVHD global severity, n (%) | |
| Moderate | 11 (19) |
| Severe | 48 (81) |
| Number of organs involved, n (%) | |
| <4 | 20 (34) |
| ≥4 | 39 (66) |
| Median lines of prior therapy (range), n | 3 (1-6) |
| cGVHD response to last systemic therapy before enrollment, n (%) | |
| PR | 12 (20) |
| SD | 25 (42) |
| PD | 12 (20) |
| Unknown | 10 (17) |
| Median number of cycles of belumosudil therapy (range), n | 14 (1-57) |
| NIH lung score at baseline, n (%) | |
| 1 (FEV1 60%-79%) | 30 (51) |
| 2 (FEV1 40%-59%) | 23 (39) |
| 3 (FEV1 <40%) | 6 (10) |
CNI, calcineurin inhibitor; m, months; MMF, mycophenolate mofetil; MTX, methotrexate; n, number; PD, progressive disease; PTCy, post-transplantation cyclophosphamide; SD, stable disease.